Ponesimod not checked

Vanda Pharmaceuticals · Actelion · ACT-128800 · VSP-128

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
4 in total · 1 in the EU
Targets
 

What this is

How it works
Sphingosine 1-phosphate Receptor Modulator FDA class
How it’s given
“Ponesimod administered orally once daily. Participants are randomized 2:1 to Ponesimod or placebo during a 16-week double-blind period. A 14-day titration is followed by a stable dose daily from Day 15 through end of treatment. Participants may enter a 36-week open-label extension receiving Ponesimod.”In the company’s words, NCT07686081 on ClinicalTrials.gov
Tested for
Moderate-to-severe Chronic Plaque Psoriasis, Ulcerative Colitis (UC)
Main trialPhase 3
“An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis”In the company’s words, NCT07362017 on ClinicalTrials.gov
Other names
ACT-128800 · VSP-128

Other drugs for Moderate-to-severe Chronic Plaque Psoriasis

All 41 drugs for Moderate-to-severe Chronic Plaque Psoriasis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Aug 2028 Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Phase 3Recruiting Apr 2029 Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
Phase 2Completed 1 Jun 2011 Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
Phase 2Completed 31 Oct 2012 ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ponesimod

Following is part of Solo: you see every change to Ponesimod the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in